Table of Contents

Benign Prostatic Hyperplasia (BPH): Causes, Symptoms, Diagnosis, Treatment and Nursing Care

Benign prostatic hyperplasia (BPH) is a non-cancerous, histological increase in the number of prostate stromal and glandular cells, usually in the transition zone around the proximal urethra. As this tissue enlarges and smooth muscle tone increases, it may narrow the prostatic urethra and contribute to bladder outlet obstruction (BOO). Men may then develop lower urinary tract symptoms (LUTS), such as a weak stream, hesitancy, frequency and nocturia. BPH, prostate enlargement, obstruction and urinary symptoms are related terms, but they are not interchangeable: some men with histological BPH have no symptoms, and LUTS can arise from the bladder, medicines, infection, diabetes, neurologic disease or other causes.

BPH is benign and is not prostate cancer. However, the two conditions can occur in the same person, and symptoms alone cannot reliably exclude cancer. Assessment is therefore directed at finding the cause of symptoms, identifying complications, discussing appropriate cancer evaluation, and choosing care according to the patient’s symptom burden, prostate characteristics, other illnesses, preferences and available services.

Urgent warning: Sudden inability to pass urine, a painful distended lower abdomen, fever with urinary symptoms, visible blood or clots in urine, recurrent infection, flank pain, or reduced kidney function requires prompt clinical assessment. Acute urinary retention is an emergency; do not delay referral or attempt forceful catheterisation.

Learning objectives

After studying this topic, the learner should be able to:

Define BPH and distinguish histological hyperplasia from benign prostatic enlargement, benign prostatic obstruction and LUTS.
Explain the anatomy, risk factors and pathophysiology linking prostate growth to bladder symptoms and complications.
Recognise storage, voiding and post-micturition symptoms and identify emergency warning signs.
Describe the focused history, examination, symptom scoring and investigations used in assessment.
Outline conservative, pharmacological and procedural management, including the nursing responsibilities and important precautions.
Plan safe acute retention care, perioperative and postoperative care, discharge teaching and follow-up.

Relevant anatomy and terminology

The prostate is a fibromuscular gland situated below the bladder and in front of the rectum. The urethra passes through the prostate before reaching the external sphincter and penis. The bladder stores urine and contracts to empty it. Normal urination therefore depends on a patent outlet, coordinated relaxation of the bladder neck and external sphincter, and a detrusor muscle capable of generating an effective contraction.

Term	Meaning	Clinical relevance
BPH	Microscopic, non-cancerous hyperplasia of glandular and stromal cells, usually in the transition zone.	Strictly a histological diagnosis. It cannot be confirmed by symptoms or prostate size alone.
Benign prostatic enlargement (BPE)	Increase in prostate size that can be estimated by examination or imaging.	An enlarged prostate may or may not obstruct urine flow or cause bothersome symptoms.
Benign prostatic obstruction (BPO)	Bladder outlet obstruction attributable to benign prostate growth.	This is a functional consequence; it is treated when it is a significant cause of symptoms or complications.
Lower urinary tract symptoms (LUTS)	Storage, voiding or post-micturition symptoms arising from the bladder, outlet or related conditions.	LUTS are not specific to BPH; assessment must consider other urological and systemic causes.
Post-void residual (PVR)	Urine remaining in the bladder immediately after urination.	A raised PVR can reflect obstruction, weak detrusor contraction or both; it does not prove BPO by itself.

Classification of symptoms and severity

Types of lower urinary tract symptoms

Group	Examples	Possible explanation
Voiding (obstructive) symptoms	Hesitancy; weak or intermittent stream; straining; prolonged voiding; terminal dribbling; feeling that urination takes longer than expected.	Increased outlet resistance may make it harder for the bladder to start or sustain urine flow. Similar symptoms can also occur with urethral stricture or detrusor weakness.
Storage symptoms	Urgency; daytime frequency; nocturia; urge incontinence.	Bladder overactivity, reduced functional capacity, infection, high fluid or urine production, heart failure, diabetes, sleep disorders and other causes can produce these symptoms.
Post-micturition symptoms	Feeling of incomplete emptying; post-micturition dribble.	May follow incomplete bladder emptying or urine retained in the urethra; symptoms alone do not identify the cause.

Symptoms often overlap. A man can have both storage and voiding symptoms, and severe symptoms do not necessarily mean a very large prostate. Ask which symptoms trouble the patient most and how they affect sleep, work, travel, relationships and quality of life.

International Prostate Symptom Score (IPSS)

The IPSS is a validated tool used to measure seven urinary symptoms and the effect of symptoms on quality of life. The seven symptom items total 0–35; the separate quality-of-life item is not added to that symptom total. The score supports baseline assessment and review of change after treatment. It does not diagnose BPH, prove obstruction, or replace history and examination.

IPSS symptom score	Usual symptom category	Interpretation for care planning
0	Asymptomatic	Interpret in the context of the patient’s concern and clinical findings.
1–7	Mild	If minimally bothersome and uncomplicated, observation and self-care may be reasonable after assessment.
8–19	Moderate	Discuss the degree of bother, risks, treatment preferences and whether further evaluation is needed.
20–35	Severe	Assess promptly for complications and consider active treatment or specialist review according to findings.

Aetiology and risk factors

The precise cause is multifactorial. Ageing and androgen-dependent prostatic tissue growth are central to the biology, but not every older man develops troublesome obstruction. Risk factors can influence prostate growth, symptom burden or disease progression.

Increasing age: BPH and LUTS become more common with age, although symptoms vary and should not be dismissed as an inevitable part of ageing.
Androgen and dihydrotestosterone (DHT) activity: DHT is formed from testosterone by 5-alpha-reductase and supports growth and maintenance of prostate tissue. It is a mechanism, not an indication for self-prescribed hormone treatment.
Family history and inherited susceptibility: A close relative with significant prostate enlargement or early intervention may increase risk.
Metabolic and cardiovascular factors: Obesity, metabolic syndrome, diabetes, hypertension and low physical activity are associated with LUTS or progression in some populations. These conditions also cause urinary symptoms independently of the prostate.
Inflammation and tissue remodelling: Inflammatory processes may contribute to growth or symptom progression in some men.
Medication effects: Decongestants with sympathomimetic activity, anticholinergic medicines, some antihistamines, opioids and other drugs can worsen voiding or precipitate retention in a susceptible patient. Diuretics may increase frequency or nocturia depending on timing.

Before attributing symptoms to BPH, review coexisting disease, medicines, fluid intake, alcohol and caffeine use, bowel habits, mobility, sleep and neurologic symptoms. A medicine may be contributing to symptoms even when it was prescribed for another important condition; the nurse should alert the prescriber rather than advise the patient to stop it independently.

Pathophysiology

Cellular hyperplasia develops: Stromal and glandular cells increase in number, mainly in the transition zone surrounding the prostatic urethra. Nodules may develop and the gland may enlarge.
The outlet becomes functionally narrower: Enlarging tissue can compress or distort the prostatic urethra. Smooth muscle tone in the prostate and bladder neck adds a dynamic component to resistance.
The bladder initially compensates: The detrusor must generate greater pressure to push urine through a narrowed outlet. Its muscle may hypertrophy and become irritable, contributing to urgency, frequency and nocturia.
Emptying may become inefficient: The bladder may take longer to empty and retain more urine. The patient can experience weak flow, incomplete emptying, terminal dribbling or overflow leakage.
Progression can cause complications: Persistent obstruction and impaired emptying may contribute to acute or chronic retention, recurrent infection, bladder stones, haematuria, bladder diverticula, hydronephrosis or renal impairment. These complications are not inevitable and require clinical assessment.
Bladder dysfunction may persist: Long-standing obstruction can impair detrusor function. Therefore, removing prostate tissue may not completely restore bladder function in every patient, especially when another bladder or neurologic disorder is present.

Important distinction: The European Association of Urology’s 2026 guideline treats male LUTS as multifactorial and focuses on benign prostatic obstruction when it is shown to be a significant cause. The prostate should not be assumed to be the cause of every urinary symptom.

Clinical manifestations

Common gradual symptoms

Difficulty initiating the urinary stream, especially after waiting to void or when the bladder is very full.
Weak stream, intermittency, straining, prolonged voiding or terminal dribbling.
Incomplete emptying or need to void again soon after urination.
Frequency, urgency or nocturia that may interrupt sleep and affect daytime function.
Occasional overflow leakage or recurrent urinary infection when emptying is poor.
Reduced quality of life, anxiety, embarrassment, reduced social activity or sexual concerns.

Complications and warning signs

Complication	Possible findings	Priority response
Acute urinary retention	Sudden inability to urinate; painful suprapubic fullness or distension; agitation, sweating or severe discomfort.	Urgent assessment and bladder drainage by a trained clinician. Escalate immediately; do not delay for routine outpatient tests.
Chronic retention / overflow	Painless persistent bladder fullness, frequent small voids, dribbling, overflow leakage, recurrent infection or renal dysfunction.	Prompt clinical and urological evaluation; assess bladder emptying and renal function as indicated.
Urinary infection or prostatitis	Dysuria, fever, rigors, suprapubic or perineal pain, cloudy urine, malaise or systemic deterioration.	Urgent review if febrile or unwell; obtain appropriate investigations and give prescribed treatment.
Haematuria or clots	Visible blood, clots, worsening stream or inability to void.	Prompt assessment. Do not assume blood is due to BPH; investigate other causes including malignancy.
Obstructive uropathy / renal impairment	Reduced urine output, raised creatinine, flank discomfort, hydronephrosis or fluid overload.	Urgent clinical review and assessment of renal function and upper urinary tract.

Assessment and diagnosis

The objectives of assessment are to identify the likely source of LUTS, measure symptom burden, look for complications, estimate the risk of progression and select tests that can change management. A single symptom or prostate size does not establish the diagnosis.

Focused history

Symptom pattern and timeline: Ask when symptoms began, whether onset was gradual or sudden, which symptoms occur during storage, voiding and after urination, and whether symptoms are stable or worsening.
Frequency, urgency and nocturia: Ask how often the patient urinates by day and night, whether urgency causes leakage, and whether thirst, large urine volumes, leg swelling, breathlessness or poor sleep may explain nocturia.
Voiding and emptying: Ask about stream strength, hesitancy, intermittency, straining, duration, terminal dribble, incomplete emptying, last successful void and prior retention or catheterisation.
Impact and preferences: Ask how symptoms affect sleep, daily activities, work, travel, mood, sexual function and quality of life. Record the patient’s treatment priorities and concerns about adverse effects.
Red-flag symptoms: Ask about visible or microscopic blood, pain, fever, recurrent UTI, urethral discharge, weight loss, bone pain, acute retention, flank pain and reduced urine output.
Medical and surgical history: Review diabetes, hypertension, heart failure, kidney disease, neurologic disease, stroke, spinal disease, prior pelvic surgery, urethral instrumentation, prostate disease and family history of prostate cancer or BPH.
Medication and substance review: Record prescribed and non-prescribed medicines, recent changes, decongestants, antihistamines, anticholinergic drugs, opioids, diuretics, alcohol, caffeine and herbal preparations.
Voiding diary: A frequency-volume chart or bladder diary, especially for nocturia, records times and volumes of urination, fluid intake and urgency. A representative diary of at least three days can reduce recall error.

Physical examination

General condition and observations: Assess temperature, pulse, blood pressure, hydration, distress and evidence of sepsis or cardiovascular compromise when clinically indicated.
Abdomen and bladder: Inspect and gently palpate the lower abdomen for a distended bladder, tenderness or mass. A palpable bladder can occur with retention; absence of a palpable bladder does not exclude it.
External genitalia and perineum: Examine as appropriate for phimosis, meatal narrowing, urethral discharge, penile lesions or another cause of obstruction. Explain the examination, obtain consent, maintain privacy and offer a chaperone according to policy.
Digital rectal examination (DRE): An appropriately trained clinician may assess prostate contour, approximate size, symmetry, texture and tenderness. BPH classically produces a smooth, symmetrically enlarged gland, but DRE estimates volume imperfectly and cannot confirm BPH. A hard, irregular, nodular or asymmetric prostate, or a tender prostate with fever, needs further evaluation.
Focused neurologic and mobility assessment: Check perineal sensation, lower-limb function, gait or other neurologic findings when the history suggests neurologic disease or impaired bladder emptying.

Investigations

Investigation	Why it is used / possible findings	Limitations and nursing considerations
IPSS and quality-of-life item	Quantifies symptom burden and provides a baseline for monitoring response.	Does not identify the cause or prove obstruction. Ensure the patient understands the questions and document the score and date.
Urinalysis: dipstick or microscopy	Looks for infection, blood, glucose and protein that may point to another diagnosis or complication.	Collect a clean-catch specimen if appropriate. Abnormal results need interpretation and follow-up; urinalysis does not diagnose BPH.
Urine culture and sensitivity	Indicated when infection is suspected or recurrent/complicated infection is being assessed; can guide antimicrobial choice.	Collect before antibiotics when this does not delay urgent treatment. Do not give antibiotics solely because LUTS are present.
Serum prostate-specific antigen (PSA)	May help estimate prostate volume or progression risk and may contribute to prostate-cancer assessment when the result could change management.	Discuss potential benefits, limitations and implications. PSA is not cancer-specific and may rise with BPH, infection, inflammation or recent manipulation. A raised result needs clinical interpretation, not a cancer diagnosis by itself.
Creatinine and estimated glomerular filtration rate (eGFR)	Assess renal function when impairment is suspected, with hydronephrosis or retention, or when surgery is being considered.	Interpret alongside hydration, diabetes, hypertension and prior results; report deterioration promptly.
Post-void residual (PVR)	Bladder scan or ultrasound estimates urine remaining after voiding and may help assess emptying or monitor risk.	A raised value does not by itself distinguish obstruction from weak detrusor contraction, and no single PVR value alone determines treatment. Record timing and clinical context.
Uroflowmetry	Measures urine flow rate and pattern. A low maximum flow can occur with outlet obstruction or weak bladder contraction.	Results depend on voided volume and patient effort; repeat if the voided volume is small or the result is not representative. It cannot diagnose the cause in isolation.
Ultrasound of prostate, bladder and upper tract	May estimate prostate volume, PVR, bladder changes, stones or hydronephrosis. Upper tract imaging is useful in selected men with large PVR, haematuria or stone history.	Choose according to the clinical question. Prostate size alone does not prove obstruction or determine symptom severity.
Cystoscopy	May be indicated for visible haematuria, suspected urethral stricture or bladder lesion, or before selected procedures.	Invasive and not required routinely for every man with uncomplicated LUTS. Explain preparation and aftercare if ordered.
Urodynamic / pressure-flow testing	May distinguish outlet obstruction from poor detrusor contraction when the diagnosis is uncertain or findings would affect invasive treatment.	Specialist-directed; not a routine first test for every patient.

PSA and 5-alpha-reductase inhibitors: Finasteride and dutasteride lower PSA by about half after several months of treatment. The prescriber must know that the patient is taking a 5-alpha-reductase inhibitor when interpreting a later PSA result. A confirmed increase from the patient’s on-treatment baseline still requires evaluation.

Differential diagnosis

Possible cause	Clues that may suggest it	Why it matters
Prostate cancer	Suspicious DRE, raised PSA, haematuria, constitutional symptoms, bone pain or other risk factors; early cancer may have no specific urinary symptoms.	Can coexist with BPH. Follow an appropriate cancer assessment pathway rather than assuming symptoms are benign.
Acute bacterial prostatitis / UTI	Fever, chills, dysuria, pelvic or perineal pain, malaise and tender prostate in some cases.	Systemic infection needs prompt treatment. Do not perform vigorous prostatic massage in suspected acute prostatitis.
Urethral stricture	Weak or spraying stream, prior urethral trauma, instrumentation, infection or surgery; may cause retention.	May need specialist imaging or endoscopic assessment; repeated blind catheter attempts can injure the urethra.
Overactive bladder or detrusor overactivity	Urgency, frequency and urge leakage may predominate without marked obstruction.	Storage symptoms can arise from bladder dysfunction even when the prostate is not the main cause.
Detrusor underactivity / neurologic bladder	Weak stream, large residual, neurologic disease, diabetes, spinal pathology or prior pelvic nerve injury.	Outlet surgery may not correct poor bladder contraction; identify the cause before treatment where possible.
Bladder stone, tumour or other bladder disease	Haematuria, recurrent infection, pain, irritative symptoms or imaging abnormalities.	Needs targeted investigation; do not attribute persistent blood to BPH without assessment.
Polyuria or nocturnal polyuria	Large urine volumes, excessive thirst, diabetes, diuretic use, heart failure, leg oedema or sleep apnoea.	Address the systemic cause and use a bladder diary when helpful; prostate treatment alone may not help.

Management of benign prostatic hyperplasia and related LUTS

Treatment is individualised. Goals include relieving bothersome symptoms, improving sleep and daily function, preventing or treating complications, preserving sexual and urinary function where possible, and enabling the patient to make an informed choice. Assess whether symptoms are actually caused by BPO before escalating prostate-directed treatment.

First contact, triage and supportive care

Identify immediate danger: Ask whether the patient can pass urine. Look for painful bladder distension, fever or rigors, haematuria with clots, flank pain, reduced output, hypotension, confusion or other signs of sepsis or renal compromise.
Escalate urgent presentations: Acute retention, sepsis, heavy haematuria/clot retention, suspected renal impairment or a painful distended bladder requires prompt medical and urological review. Arrange transfer to an appropriate facility when needed.
Support and reassess: Provide privacy, reassurance and a comfortable position. Record observations, pain, last void, urine findings and medicines. In an unwell patient follow local emergency assessment and sepsis pathways.
Do not delay emergency drainage for routine investigations: If retention is confirmed or strongly suspected, bladder drainage is arranged by a trained clinician under local protocol. A bladder scan may help if available but should not delay necessary care.
Document and hand over: Communicate onset, last void, symptoms, observations, bladder-scan/PVR result if available, renal history, medication risks, allergies and any catheter attempt or prior urethral procedure.

Acute urinary retention

Acute urinary retention is sudden inability to empty the bladder, commonly with painful suprapubic distension. It may be precipitated by BPO, infection, constipation, alcohol, surgery, anaesthesia, immobility or medicines such as sympathomimetic decongestants and anticholinergics. It is a complication requiring urgent clinician-led management, not a condition for home observation.

Step	Action	Rationale and nursing responsibility
1	Recognise inability to pass urine, suprapubic pain or fullness, distress and possible overflow leakage. Record observations and notify the senior clinician urgently.	Early recognition prevents prolonged painful distension and missed sepsis or renal complications.
2	Assess recent voiding, haematuria, fever, prior catheterisation, urethral stricture, pelvic surgery, trauma and medication use. Obtain bladder scan/PVR if available and appropriate.	Identifies possible triggers and factors that make urethral catheterisation difficult or unsafe.
3	A trained clinician performs aseptic urethral catheterisation when appropriate and ordered. If there is resistance, severe pain, bleeding, known stricture, recent urethral/prostate surgery or concern for urethral injury, stop and seek experienced urological help; never force the catheter or make repeated blind attempts.	Traumatic instrumentation can cause bleeding, false passage or urethral injury. A suprapubic catheter may be considered by a suitably trained clinician when urethral drainage is not possible or appropriate.
4	Record the time, catheter type/size as documented by the clinician, initial volume drained, urine appearance, pain response and ongoing output. Maintain a closed drainage system and secure the catheter without traction.	Accurate documentation supports assessment of retention, haematuria, fluid balance and device function.
5	Monitor for haematuria, clots, poor drainage, bladder spasms, hypotension, post-obstructive diuresis and electrolyte or renal abnormalities when clinically indicated, especially after substantial retention.	Rapid drainage can be followed by bleeding or high urine output in some patients. Escalate worsening pain, blocked catheter, faintness, large ongoing losses or deterioration.
6	The prescriber may start an alpha-1 blocker before a planned trial without catheter. Review the cause of retention, treatment response and follow-up plan before discharge.	Alpha-blockers can improve the chance of successful catheter removal in selected men, but do not prevent long-term progression by themselves.

Watchful waiting and self-care

After assessment, watchful waiting is reasonable for many men with mild or moderately bothersome symptoms who have no complication and prefer to avoid medication or surgery. It means active review and self-care, not ignoring symptoms. Agree on what worsening looks like and how the patient can return for care.

Fluid timing: Maintain adequate hydration, but consider reducing large drinks shortly before sleep or travel if nocturia is troublesome. Avoid excessive fluid restriction, which can cause dehydration.
Bladder habits: Avoid unnecessarily delaying urination. A second attempt to void shortly after the first (double voiding) may help some patients who feel incompletely emptied.
Reduce symptom triggers: Caffeine and alcohol can worsen urgency or nocturia in some people. Individualise advice and assess whether symptoms actually improve when intake is reduced.
Review medicine timing and burden: The prescriber may adjust the timing of diuretics or review medicines that worsen voiding. Patients should not stop prescribed medicines on their own.
Address constipation, mobility and metabolic health: Treat constipation, encourage appropriate activity and support management of diabetes, obesity and cardiovascular disease.
Follow-up: Review symptom score, bother, adverse effects, urine findings and signs of retention or renal impairment according to risk and local service arrangements.

Pharmacological treatment

Choice depends on the predominant symptoms, prostate size/progression risk, comorbidities, sexual priorities, adverse-effect profile, medicine availability and patient preference. The doses below are common adult examples for teaching, not a prescription for an individual; clinicians must follow current national guidance, local formulary, product information and patient-specific contraindications.

Medicine group	Examples and typical adult regimen	How it helps and when considered	Important adverse effects / nursing points
Alpha-1 adrenergic blockers	Tamsulosin 0.4 mg orally once daily is a common starting regimen; alfuzosin, doxazosin and terazosin are alternatives with different dose and blood-pressure considerations.	Relax smooth muscle in the prostate and bladder neck, reducing the dynamic component of outlet resistance. Often gives relatively rapid relief in moderate-to-severe bothersome LUTS.	Dizziness, postural hypotension, weakness and ejaculatory dysfunction may occur. Check falls risk and blood pressure where indicated. Tell the prescriber and ophthalmologist before cataract surgery because of intraoperative floppy iris syndrome risk. These medicines improve symptoms but do not reliably prevent prostate growth, retention or future surgery.
5-alpha-reductase inhibitors (5-ARIs)	Finasteride 5 mg orally once daily or dutasteride 0.5 mg orally once daily are common adult regimens for men with an enlarged prostate and progression risk.	Reduce conversion of testosterone to DHT and gradually shrink prostate tissue. Consider for moderate-to-severe symptoms when enlargement is documented or strongly suspected and long-term progression reduction is important.	Benefit is slow and may take several months; explain why early lack of change does not automatically mean failure. Possible reduced libido, erectile or ejaculatory problems, breast tenderness and mood change. These medicines lower PSA; record treatment and ensure results are interpreted accordingly. Pregnant people should not handle crushed/broken finasteride tablets or leaking dutasteride capsules because of potential risk to a male fetus.
Alpha-blocker plus 5-ARI	For example, tamsulosin with dutasteride, when prescribed.	Combines faster smooth-muscle relaxation with slower reduction of prostate volume and progression risk; considered for selected men with significant symptoms and enlarged prostate at higher risk of progression.	Adverse effects from both medicines may occur, including dizziness, sexual adverse effects and ejaculatory dysfunction. Review symptom benefit, blood pressure, falls risk, sexual concerns and adherence; treatment can be reassessed after sustained response.
Phosphodiesterase type 5 inhibitor	Tadalafil 5 mg orally once daily is the usual LUTS regimen where appropriate.	Can improve LUTS and erectile dysfunction in some men; may be useful when both matter to the patient. It may improve symptom scores without substantially increasing maximum flow or shrinking the prostate.	Headache, flushing, dyspepsia, back pain and hypotension can occur. Do not use with nitrate medicines or riociguat; review cardiovascular status and interacting medicines. Check local product information and prescriber advice.
Antimuscarinic medicine for storage symptoms	Examples include solifenacin, tolterodine or oxybutynin; exact choice and dose are prescriber-led.	May be considered when urgency, frequency or urge incontinence predominate, after assessing emptying and retention risk.	Dry mouth, constipation, blurred vision and cognitive adverse effects can occur, especially in older adults. These medicines may increase residual urine; monitor symptoms and PVR as ordered and report inability to void.
Beta-3 agonist for storage symptoms	Mirabegron is an example; regimen depends on formulation and patient factors.	Relaxes the bladder during storage and can reduce urgency and frequency in selected men.	Monitor blood pressure and urinary emptying as directed. Use caution with uncontrolled hypertension or retention risk. It treats storage symptoms, not the underlying prostate enlargement.
Antibiotics	Only when bacterial infection is clinically suspected or confirmed and treatment is prescribed.	Antibiotics do not treat uncomplicated BPH and should not be given just because a man has LUTS.	Collect appropriate cultures when indicated, check allergy and renal function, support completion of the prescribed course and monitor response and adverse effects.

Procedural and surgical treatment

Urological intervention is considered when symptoms remain troublesome despite appropriate conservative or drug treatment, the patient prefers a procedure after informed discussion, or complications make definitive relief of obstruction necessary. Procedure choice depends on prostate size and anatomy, bladder function, comorbidities, bleeding risk, anaesthetic fitness, sexual priorities, available equipment and surgical expertise.

Common indications for surgery or specialist intervention

Recurrent or refractory urinary retention, or overflow incontinence related to BPO.
Recurrent urinary tract infection attributable to poor emptying.
Bladder stones or diverticula associated with obstruction.
Persistent visible haematuria attributed to BPH/BPE after other causes are considered and treatment is unsuccessful.
Upper urinary tract dilatation or renal impairment related to BPO.
Bothersome LUTS or persistently poor emptying despite appropriate conservative and medical therapy.

Selected procedures

Transurethral resection of the prostate (TURP): A resectoscope is passed through the urethra and obstructing transition-zone tissue is removed. It is a common operation for moderate-sized glands where expertise and equipment are available.
Transurethral incision of the prostate (TUIP): One or more incisions widen the bladder outlet without removing substantial tissue. It may suit selected men with a small prostate and no obstructing middle lobe; retreatment can be more common than after TURP.
Laser enucleation or vaporisation: Procedures such as holmium laser enucleation (HoLEP) or photoselective vaporisation remove or ablate obstructing tissue. Suitability depends on anatomy, equipment and experienced staff.
Simple prostatectomy: For very large glands, an open, laparoscopic or robotic approach may remove the obstructing adenoma while leaving the prostate capsule. This is different from radical prostatectomy for cancer.
Minimally invasive options: Prostatic urethral lift, water-vapour therapy, aquablation and prostate artery embolisation may be considered for selected patients where available, with procedure-specific trade-offs, follow-up and retreatment risks.

Potential complications include bleeding, infection, transient urgency or dysuria, urinary incontinence, erectile or ejaculatory changes, retrograde ejaculation, urethral stricture, bladder-neck contracture, persistent symptoms, retention and need for repeat treatment. The surgeon should explain likely benefits and risks for the proposed procedure and the patient’s own priorities.

Nursing management

Nursing care supports safe assessment, relief of symptoms, early recognition of deterioration, effective treatment, privacy and informed self-management. Care must remain within the nurse’s training, scope of practice and local protocols; catheterisation, medicines, bladder irrigation and other interventions require appropriate training and authorisation.

Priority nursing assessment

Establish whether the patient can void, when he last voided, the pattern and volume of urine, pain, urgency, nocturia, leakage, haematuria, fever and prior retention.
Record baseline symptom score and quality-of-life impact when this is part of the plan; do not interpret the score as a diagnosis.
Assess vital signs, hydration, suprapubic fullness, pain, urine appearance, mobility and fall risk. In an acute presentation, look for infection, shock, clot retention and renal compromise.
Review allergies, prescribed and non-prescribed medicines, comorbidities, renal function results and planned investigations. Clarify concerns about sexual effects or cataract surgery before treatment changes.
Preserve privacy and dignity during urinary, abdominal or rectal examinations. Explain each step, obtain consent, offer a chaperone and document relevant findings according to policy.

Nursing care plan examples

Nursing problem and desired outcome	Nursing interventions	Rationale and evaluation
Impaired urinary elimination related to outlet resistance or incomplete emptying. Goal: Patient passes urine or has a safe drainage plan, with changes recognised promptly.	Assess voiding pattern, last void, pain, bladder fullness, urine appearance and PVR if ordered. Measure intake/output when indicated. Assist the patient to toilet privately and safely. Escalate retention, new haematuria, fever or reduced output. Maintain a prescribed catheter and closed drainage system using aseptic technique.	Trend changes may reveal worsening obstruction, infection, bleeding or renal compromise. Evaluate by documenting voiding/drainage, symptoms, residual or output where measured, and response to treatment.
Acute pain related to bladder distension, infection or a procedure. Goal: Pain decreases to an acceptable level and urgent causes are treated.	Assess location, severity, onset and associated symptoms. Do not label severe suprapubic pain as routine BPH. Notify the clinician urgently for acute retention or infection. Give prescribed analgesia and reassess effect and adverse reactions.	Pain may indicate retention, infection or another acute condition. Evaluate pain score, comfort, ability to rest and whether the underlying cause has been addressed.
Disturbed sleep / fatigue related to nocturia. Goal: Patient identifies practical strategies and reports improved sleep when possible.	Assess number of night voids and sleep impact; use a frequency-volume diary if ordered. Discuss safe evening fluid timing, caffeine/alcohol triggers, leg oedema, sleep problems and diuretic timing with the prescriber.	Nocturia has multiple causes. Individualised management is more likely to help than assuming the prostate is responsible. Evaluate diary and patient-reported sleep over follow-up.
Risk of infection related to urinary stasis or catheterisation. Goal: No untreated infection develops and the patient knows when to seek care.	Use hand hygiene and aseptic technique for catheter care; maintain unobstructed closed drainage; avoid unnecessary catheter disconnection; monitor temperature, urine and symptoms; obtain cultures and administer antibiotics only as ordered.	Urinary stasis and devices increase infection risk. Evaluate for fever, dysuria, rigors, suprapubic pain, urine culture results and response to prescribed treatment.
Knowledge deficit or anxiety related to urinary symptoms, cancer concerns or treatment choices. Goal: Patient explains the agreed plan, warning signs and follow-up.	Explain the difference between BPH and prostate cancer without false reassurance. Discuss investigations, expected medicine onset, adverse effects, sexual concerns and when to return. Use teach-back and involve family only with the patient’s consent.	Clear education supports adherence and shared decisions. Evaluate by asking the patient to describe the plan and identify urgent symptoms.
Risk of bleeding or catheter obstruction after prostate surgery. Goal: Haemorrhage and obstruction are identified and escalated early.	Monitor vital signs, urine colour, clots, catheter flow, bladder discomfort and ordered haemoglobin. If continuous bladder irrigation (CBI) is prescribed, maintain the ordered system, measure inflow and drainage accurately, and calculate actual urine as drainage minus irrigant. Report reduced drainage, bladder distension, large clots, bright-red bleeding or haemodynamic change. Do not independently alter the irrigation prescription.	Clot retention can cause painful bladder distension and obstruct drainage. Accurate fluid balance helps detect bleeding and high irrigation inflow. Evaluate for patent drainage, improving urine colour, stable observations and documented net urine output.

Perioperative and postoperative nursing care

Before the procedure: Confirm patient identity, consent, planned procedure, allergies, anticoagulant/antiplatelet plan, relevant investigations and fasting instructions. Explain the catheter, possible irrigation, expected recovery and the limits of what can be predicted about sexual or urinary outcomes.
After the procedure: Monitor airway and recovery from anaesthesia, vital signs, pain, urine output, catheter patency, urine colour, clots and fluid balance. Reassess promptly after any intervention.
Maintain catheter and irrigation safety: Keep tubing unkinked and bag below bladder level when appropriate. For prescribed CBI, ensure the irrigation inflow and drainage remain connected and flowing; never allow the bladder to distend because of a blocked outflow. Notify the clinician urgently if drainage falls or stops.
Recognise bleeding and clot retention: Escalate increasing bright-red haematuria, repeated large clots, increasing suprapubic pain/distension, blocked catheter, pallor, tachycardia, hypotension or falling haemoglobin. Do not perform manual irrigation unless trained, authorised and directed by the local order/protocol.
Watch for infection and fluid/electrolyte problems: Monitor temperature, mental state, nausea, headache, confusion, visual symptoms, breathlessness and ordered electrolytes. TUR syndrome is uncommon with modern techniques but fluid absorption and other postoperative complications still require prompt recognition.
Promote recovery: Provide prescribed analgesia, encourage early mobilisation when safe, support hydration as directed, prevent constipation and follow the prescribed venous thromboembolism and wound-care plans.
Prepare for catheter removal and discharge: Follow the urology plan for trial without catheter, document voiding and residual if measured, explain any expected urinary urgency or mild transient blood according to the surgeon’s instructions, and ensure the patient knows when and where to return.

Patient education, discharge and prevention

Explain that BPH is benign tissue growth, but symptoms need assessment because prostate cancer, infection, urethral stricture, bladder disease and systemic causes can look similar or coexist.
Take medicines exactly as prescribed. Alpha-blockers may improve symptoms sooner, while 5-ARIs act slowly over months. Do not stop treatment or add over-the-counter cold remedies or herbal products without discussing them with a clinician.
Rise slowly if taking an alpha-blocker and report faintness or falls. Tell an eye surgeon about current or previous alpha-blocker use before cataract surgery.
Report new breast changes, mood changes, troublesome sexual effects, allergy or other adverse reactions. Discuss concerns privately; sexual and reproductive wellbeing are part of care.
Maintain reasonable hydration; consider reducing large late-evening drinks, excess caffeine or alcohol only if these worsen symptoms. Do not dehydrate yourself to reduce urination.
Seek urgent help for inability to pass urine, fever/rigors, visible blood or clots, severe lower-abdominal pain, flank pain, markedly reduced urine, vomiting or confusion.
Attend the agreed follow-up for symptom review, medication response, adverse effects, PSA or renal monitoring when indicated, and review of PVR or flow tests if ordered.
After prostate surgery, follow the surgeon’s activity, lifting, fluid, catheter and sexual-activity instructions. Return for heavy bleeding, clots, blocked catheter, fever, worsening pain, inability to void or faintness.

Prevention: There is no guaranteed way to prevent age-related BPH. Healthy weight, regular activity, diabetes and cardiovascular risk management, treatment of constipation and careful medicine review can support general health and may reduce some symptom aggravators. These measures do not replace assessment or treatment when obstruction or complications are present.

Case-based application

A 68-year-old man reports a year of worsening weak stream, hesitancy, straining and waking three times each night to urinate. He has no fever or visible blood. He recently started an over-the-counter decongestant for a cold. The nurse records his symptom history, medication use, quality-of-life impact and observations, then arranges clinical review rather than assuming that prostate enlargement is the only cause. Urinalysis and a validated symptom score are considered; the clinician performs an appropriate examination and decides whether PSA, PVR, renal tests or imaging would change management. The patient and clinician discuss self-care, medicines and follow-up. If he later becomes unable to void with painful suprapubic distension, that is acute retention and requires urgent drainage by a trained clinician, not a routine appointment.

Common errors to avoid

Equating BPH with prostate cancer, or telling the patient that BPH symptoms automatically mean cancer.
Assuming all male LUTS arise from the prostate or that prostate size directly predicts symptom severity.
Diagnosing BPH from a symptom score, PSA value, DRE or ultrasound finding alone.
Using antibiotics for uncomplicated LUTS without evidence or clinical suspicion of bacterial infection.
Ignoring acute retention, haematuria, fever, renal impairment or recurrent infection as urgent warning signs.
Forcing a catheter or making repeated blind attempts when there is resistance, trauma, urethral stricture or recent urological surgery.
Expecting a 5-ARI to provide rapid relief, or forgetting that it lowers PSA and changes interpretation.
Ignoring orthostatic hypotension, falls risk, cataract surgery or sexual adverse effects when counselling about alpha-blockers.
Advising a patient to stop prescribed medicines or restrict all fluids without reviewing the cause and risks.
Failing to measure actual urine output during CBI by subtracting the irrigation volume from total drainage.

Revision questions

Define BPH and distinguish it from benign prostatic enlargement, benign prostatic obstruction and lower urinary tract symptoms.
List the storage, voiding and post-micturition symptoms associated with male LUTS.
Explain how prostate tissue growth and smooth-muscle tone can affect urine flow and bladder function.
State the IPSS severity categories and explain why the IPSS does not diagnose BPH.
Describe five key areas in a focused history and four important examination findings or considerations.
What are the roles and limitations of urinalysis, PSA, PVR and uroflowmetry in assessment?
Give four differential diagnoses for LUTS and one clue for each.
Outline the immediate response to acute urinary retention and state when catheter attempts must stop.
Compare the actions, onset, progression benefit and key adverse effects of alpha-blockers and 5-ARIs.
List common indications for procedural or surgical treatment and describe two surgical options.
Describe nursing care for a patient with a three-way catheter and prescribed CBI after TURP.
List the discharge advice and warning signs a patient should understand before leaving hospital.

Key points to remember

BPH is a histological, non-cancerous increase in prostate cells; prostate enlargement, obstruction and LUTS are related but distinct concepts.
Male LUTS are multifactorial. Assess the bladder, medicines, infection, diabetes, neurologic conditions, nocturnal polyuria and possible malignancy where indicated.
Use history, validated symptom scoring, examination and targeted investigations; no single test proves BPH or obstruction.
Acute inability to void with a painful distended bladder requires urgent clinician-led drainage and monitoring.
Alpha-blockers can relieve symptoms quickly but do not prevent progression; 5-ARIs act slowly, reduce prostate volume and can reduce retention or surgery risk in appropriately selected men with enlargement.
Recurrent retention, infection, stones, persistent haematuria, upper tract dilatation or renal impairment may require urgent specialist management or surgery.
Nursing care includes privacy, accurate voiding and fluid assessment, medicine safety, aseptic catheter care, early escalation and clear follow-up teaching.

References and further reading

European Association of Urology (EAU). Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. 2026 edition; sections on introduction, epidemiology/pathophysiology, diagnostic evaluation, disease management and follow-up.
American Urological Association (AUA). Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: Guideline. 2023 amendment.
U.S. National Library of Medicine, DailyMed. Tamsulosin hydrochloride prescribing information; finasteride prescribing information; and tadalafil prescribing information.
Use the current Uganda Ministry of Health guidance, local referral pathways, institutional catheterisation and infection-prevention policies, and current formulary when applying treatment. Prescribing and procedures require clinician assessment and appropriate scope, training and authorisation.